Valeant Pharmaceuticals Intl Inc (NYSE:VRX) wholly owned subsidiary, Bausch + Lomb, announced it has received 510(k) clearance from the FDA for the Stellaris …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced that Louis W. Yu, Ph.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) reported consolidated financial results for the quarter ended March 31, 2016 and provided an update on its approved …
Valeant Pharmaceuticals (NYSE: VRX) held a conference call with investors on Thursday, January 8th, in which the company increased its guidance for 2015. Initially, …
In a research report issued Tuesday, Cantor analyst Irina Rivkind maintained a Buy rating on Valeant Pharmaceuticals (NYSE:VRX) and raised his price target to $182 …
In a research report issued today, Canaccord Genuity analyst Neil Maruoka maintained a Buy rating on Valeant Pharmaceuticals (NYSE:VRX) with a price target of …
